Moreover, Fib is reported to be an important biomarker reflecting systemic inflammation [37] and it serves as a candidate prognostic biomarker in patients with non-small cell lung cancer (NSCLC) [38]. This evidence concerns the gene FBL and non-small cell lung carcinoma.